[
    {
        "file_name": "novointegratedsciences,inc_12_23_2019-ex-10.1-joint venture agreement.pdf",
        "perturbation": [
            {
                "type": "Misaligned Terminology - Legal Contradiction",
                "original_text": "(c) “Company” means the Joint Venture entity which will be registered and incorporated in a Canadian jurisdiction with its operating name as\nNovo Earth Therapeutics Inc.",
                "changed_text": "(c) “Company” means the Joint Venture entity which will be operated as a division of NVOS and will not be registered or incorporated as a separate legal entity.",
                "explanation": "The original text defines the Joint Venture as a separate incorporated entity, whereas the modified text states that it will not be registered or incorporated, directly contradicting the initial definition. This introduces uncertainty about the legal structure and liability of the joint venture under Canadian corporate law.",
                "contradicted_law": "Canadian corporate law regarding the establishment and operation of joint ventures and separate legal entities.",
                "location": "ARTICLE 1 - DEFINITIONS AND INTERPRETATION, 1.1"
            },
            {
                "type": "Misaligned Terminology - Legal Contradiction",
                "original_text": "9.3\nTo remunerate HGF on the basis of thirty percent (30%) of net Company income basis on an annual basis commencing 12 months after the\nfirst full 12-month revenue period.",
                "changed_text": "9.3\nTo remunerate HGF at NVOS's discretion, potentially up to thirty percent (30%) of net Company income, contingent on NVOS's overall profitability.",
                "explanation": "The original text defines the Joint Venture as a separate incorporated entity, whereas the modified text states that it will not be registered or incorporated, directly contradicting the initial definition. This introduces uncertainty about the legal structure and liability of the joint venture under Canadian corporate law.",
                "contradicted_law": "Contract law principles regarding definite terms and enforceability.",
                "location": "ARTICLE 9 - OBLIGATIONS OF NVOS, 9.3"
            },
            {
                "type": "Misaligned Terminology - Legal Contradiction",
                "original_text": "12.1\nThe distribution will be based on NVOS audited review and will be made within three months of annual considerations on the basis of a\nseventy percent (70%) of net profit to NVOS and thirty percent (30%) of net profit to HGF.",
                "changed_text": "12.1\nThe distribution will be based on NVOS's assessment of available funds, which may or may not align with audited net profit, and will be distributed at NVOS's convenience.",
                "explanation": "The original text specifies a clear distribution based on audited net profit with a fixed percentage split. The modified text makes the distribution discretionary based on NVOS's assessment and convenience, contradicting the originally agreed-upon terms and creating uncertainty regarding the distribution process. Also the changed text removes the clear split between both entities.",
                "contradicted_law": "Contract law principles regarding definite terms and enforceability.",
                "location": "ARTICLE 12 - DIVIDEND DISTRIBUTIONS, 12.1"
            }
        ]
    }
]